Shen Haiyuan, Liangpunsakul Suthat, Iwakiri Yasuko, Szabo Gyongyi, Wang Hua
Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China.
Cell Mol Immunol. 2025 May 21. doi: 10.1038/s41423-025-01291-w.
Alcohol-associated liver disease (ALD) is a major global health challenge, with inflammation playing a central role in its progression. As inflammation emerges as a critical therapeutic target, ongoing research aims to unravel its underlying mechanisms. This review explores the immunological pathways of ALD, highlighting the roles of immune cells and their inflammatory mediators in disease onset and progression. We also examine the complex interactions between inflammatory cells and non-parenchymal liver cells, as well as their crosstalk with extra-hepatic organs, including the gut, adipose tissue, and nervous system. Furthermore, we summarize current clinical research on anti-inflammatory therapies and discuss promising therapeutic targets. Given the heterogeneity of ALD-associated inflammation, we emphasize the need for precision medicine to optimize treatment strategies and improve patient outcomes.
酒精性肝病(ALD)是一项重大的全球健康挑战,炎症在其进展过程中起核心作用。随着炎症成为关键的治疗靶点,正在进行的研究旨在揭示其潜在机制。本综述探讨了ALD的免疫途径,强调了免疫细胞及其炎症介质在疾病发生和进展中的作用。我们还研究了炎症细胞与非实质肝细胞之间的复杂相互作用,以及它们与肝外器官(包括肠道、脂肪组织和神经系统)的串扰。此外,我们总结了目前关于抗炎治疗的临床研究,并讨论了有前景的治疗靶点。鉴于ALD相关炎症的异质性,我们强调需要精准医学来优化治疗策略并改善患者预后。